Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Flow cytometry [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-26129 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- DIPA Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with mouse based on sequence homology.
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 400 µL
- Concentration
- 2 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.
Feng Y, Gao Y, Yu J, Jiang G, Zhang X, Lin X, Han Q, Rong X, Xu H, Li Q, Qiu X, Wang E
Molecular carcinogenesis 2019 Jan;58(1):126-134
Molecular carcinogenesis 2019 Jan;58(1):126-134
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of DIPA in HepG2 cell line lysates. Samples were incubated with DIPA polyclonal antibody (Product # PA5-26129). Lysates: 35 µg/lane. DIPA (arrow).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of DIPA in formalin-fixed and paraffin-embedded human skeletal muscle. Samples were incubated with DIPA polyclonal antibody (Product # PA5-26129) which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry analysis of HepG2 cells using a DIPA polyclonal antibody (Product # PA5-26129) (right) compared to a negative control cell (left) at a dilution of 1:10-50, followed by a FITC-conjugated goat anti-rabbit antibody
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometry of DIPA in HepG2 cells (right histogram). Samples were incubated with DIPA polyclonal antibody (Product # PA5-26129) followed by FITC-conjugated goat-anti-rabbit secondary antibody. Negative control cell (left histogram).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- CCDC85B upregulated active beta-catenin, Wnt targets c-myc, cyclin D1, and MMP-7. WB analysis showed that CCDC85B overexpression downregulated the phosphorylated beta-catenin and upregulated the phosphorylated GSK3beta, active beta-catenin, and its downstream factors: c-myc, cyclin D1, and MMP-7 in A549 and H1299 cells (A). CCDC85B knockdown displayed opposite effects (B). Immunofluorescence assays showed that CCDC85B overexpression upregulated the nuclear beta-catenin in A549 and H1299 cells (C, D)
